Merck & Co Inc
MRK106.850USD
+0.400+0.38%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
265.77BMarket Cap
14.10P/E TTM
More Details of Merck & Co Inc Company
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Merck & Co Inc Info
Ticker SymbolMRK
Company nameMerck & Co Inc
IPO dateFeb 06, 2077
CEODavis (Robert M)
Number of employees75000
Security typeOrdinary Share
Fiscal year-endFeb 06
Address126 East Lincoln Avenue
CityRAHWAY
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code07065
Phone19087404000
Websitehttps://www.merck.com/
Ticker SymbolMRK
IPO dateFeb 06, 2077
CEODavis (Robert M)
Company Executives of Merck & Co Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
443.60K
--
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
185.33K
+17.90%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
85.34K
+28.11%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
79.59K
+0.92%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
53.42K
+90.81%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
22.91K
+5.27%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
Other
4.47B
28.27%
By RegionUSD
Name
Revenue
Proportion
United States
8.84B
55.90%
Europe, Middle East and Africa
3.66B
23.15%
Latin America
859.00M
5.43%
Asia Pacific (Other than China and Japan)
785.00M
4.97%
Japan
626.00M
3.96%
Other
1.04B
6.59%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oncology-Keytruda
7.96B
50.34%
Vaccines -Gardasil/Gardasil
1.13B
7.12%
Animal Health-Livestock
961.00M
6.08%
Animal Health-Companion Animals
685.00M
4.33%
Vaccines -ProQuad/M-M-R II/Varivax
609.00M
3.85%
Other
4.47B
28.27%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
Other
74.00%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.11%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
Other
74.00%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.31%
Investment Advisor/Hedge Fund
26.78%
Research Firm
3.18%
Pension Fund
2.51%
Bank and Trust
2.21%
Sovereign Wealth Fund
1.55%
Hedge Fund
1.06%
Insurance Company
0.69%
Family Office
0.13%
Other
19.59%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
5358
2.02B
81.35%
-45.75M
2025Q2
5398
2.02B
80.82%
-16.42M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
2023Q2
4864
2.00B
78.94%
-18.54M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
251.75M
10.08%
+356.59K
+0.14%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
142.78M
5.72%
-4.51M
-3.06%
Jun 30, 2025
State Street Investment Management (US)
118.49M
4.74%
-2.04M
-1.69%
Jun 30, 2025
Wellington Management Company, LLP
76.86M
3.08%
-4.81M
-5.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
58.95M
2.36%
-704.59K
-1.18%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
53.87M
2.16%
+4.64M
+9.42%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
36.11M
1.45%
+1.13M
+3.23%
Jun 30, 2025
Fidelity Management & Research Company LLC
28.48M
1.14%
+229.47K
+0.81%
Jun 30, 2025
Fisher Investments
25.01M
1%
+567.90K
+2.32%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
22.79M
0.91%
+764.14K
+3.47%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Pharmaceutical ETF
16.09%
FT Vest DJIA Dogs 10 Target Income ETF
10.79%
First Trust NASDAQ Pharmaceuticals ETF
7.94%
Invesco Dow Jones Industrial Average Dividend ETF
6.94%
First Trust Morningstar Dividend Leaders Index Fund
5.39%
Coastal Compass 100 ETF
5.13%
Invesco Pharmaceuticals ETF
4.96%
VanEck Morningstar Wide Moat Value ETF
4.73%
Vaneck Durable High Dividend ETF
4.65%
Franklin Income Focus ETF
4.56%
View more
VanEck Pharmaceutical ETF
Proportion16.09%
FT Vest DJIA Dogs 10 Target Income ETF
Proportion10.79%
First Trust NASDAQ Pharmaceuticals ETF
Proportion7.94%
Invesco Dow Jones Industrial Average Dividend ETF
Proportion6.94%
First Trust Morningstar Dividend Leaders Index Fund
Proportion5.39%
Coastal Compass 100 ETF
Proportion5.13%
Invesco Pharmaceuticals ETF
Proportion4.96%
VanEck Morningstar Wide Moat Value ETF
Proportion4.73%
Vaneck Durable High Dividend ETF
Proportion4.65%
Franklin Income Focus ETF
Proportion4.56%
Dividend
A total of
35.12B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Nov 18, 2025
MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Jan 08, 2026 going ex on Dec 15, 2025
Dec 15, 2025
Jan 08, 2026
Dec 15, 2025
Jul 22, 2025
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Oct 07, 2025 going ex on Sep 15, 2025
Sep 15, 2025
Oct 07, 2025
Sep 15, 2025
May 27, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Jul 08, 2025 going ex on Jun 16, 2025
Jun 16, 2025
Jul 08, 2025
Jun 16, 2025
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Merck & Co Inc?
The top five shareholders of Merck & Co Inc are:
The Vanguard Group, Inc. holds 251.75M shares, accounting for 10.08% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 142.78M shares, accounting for 5.72% of the total shares.
State Street Investment Management (US) holds 118.49M shares, accounting for 4.74% of the total shares.
Wellington Management Company, LLP holds 76.86M shares, accounting for 3.08% of the total shares.
Geode Capital Management, L.L.C. holds 58.95M shares, accounting for 2.36% of the total shares.
The Vanguard Group, Inc. holds 251.75M shares, accounting for 10.08% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 142.78M shares, accounting for 5.72% of the total shares.
State Street Investment Management (US) holds 118.49M shares, accounting for 4.74% of the total shares.
Wellington Management Company, LLP holds 76.86M shares, accounting for 3.08% of the total shares.
Geode Capital Management, L.L.C. holds 58.95M shares, accounting for 2.36% of the total shares.
What are the top three shareholder types of Merck & Co Inc?
The top three shareholder types of Merck & Co Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Merck & Co Inc (MRK)?
As of 2025Q3, 5358 institutions hold shares of Merck & Co Inc, with a combined market value of approximately 2.02B, accounting for 81.35% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.53%.
What is the biggest source of revenue for Merck & Co Inc?
In FY2025Q2, the Oncology-Keytruda business generated the highest revenue for Merck & Co Inc, amounting to 7.96B and accounting for 50.34% of total revenue.
